

Case series of individuals with analytically confirmed a

Clinical Toxicology

48, 924-927

DOI: 10.3109/15563650.2010.531021

Citation Report

#	ARTICLE	IF	CITATIONS
1	Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic) Tj ETQq0,0,0 rgBT /Overlock 1	1.9	487
2	Clinical toxicology of newer recreational drugs. Clinical Toxicology, 2011, 49, 705-719.	1.9	250
5	Clean But Not Sober. Pediatric Emergency Care, 2011, 27, 892-894.	0.9	2
6	Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. British Journal of Pharmacology, 2011, 164, 1949-1958.	5.4	277
7	The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Testing and Analysis, 2011, 3, 454-463.	2.6	139
8	Synthesis, full chemical characterisation and development of validated methods for the quantification of (±)-4-methylmethcathinone (mephedrone): A new "legal high". Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 246-255.	2.8	51
9	Survey of ICD-10 coding of hospital admissions in the UK due to recreational drug toxicity. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 779-784.	0.5	28
10	Analytical Toxicology of Emerging Drugs of Abuse" An Update. Therapeutic Drug Monitoring, 2012, 34, 615-621.	2.0	32
11	Bath Salt Use: A Case Report and Review of the Literature. Journal of Dual Diagnosis, 2012, 8, 250-256.	1.2	16
12	Novel Psychoactive Substances. Therapeutic Drug Monitoring, 2012, 34, 363-367.	2.0	62
13	Miaow miaow: a review of the new psychoactive drug mephedrone. Drugs and Alcohol Today, 2012, 12, 241-253.	0.7	12
14	New "Lethal highs": A case of a deadly cocktail of GHB and Mephedrone. Forensic Science International, 2012, 223, e38-e41.	2.2	42
15	"Bath Salt" Ingestion Leading to Severe Intoxication Delirium: Two Cases and a Brief Review of the Emergence of Mephedrone Use. American Journal of Drug and Alcohol Abuse, 2012, 38, 176-180.	2.1	71
16	Understanding How Data Triangulation Identifies Acute Toxicity of Novel Psychoactive Drugs. Journal of Medical Toxicology, 2012, 8, 300-303.	1.5	47
17	Mephedrone ("bath salt") pharmacology: insights from invertebrates. Neuroscience, 2012, 208, 79-84.	2.3	39
18	3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicology Letters, 2012, 208, 12-15.	0.8	136
19	Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicology Letters, 2012, 208, 62-68.	0.8	37
20	Research chemicals marketed as legal highs: The case of pipradrol derivatives. Toxicology Letters, 2012, 212, 57-60.	0.8	16

#	ARTICLE	IF	CITATIONS
21	In vivo comparison of harmine efficacy against psychostimulants: Preferential inhibition of the cocaine response through a glutamatergic mechanism. <i>Neuroscience Letters</i> , 2012, 525, 12-16.	2.1	16
22	Synthetic Cathinones (Bath Salts): Legal Status and Patterns of Abuse. <i>Annals of Pharmacotherapy</i> , 2012, 46, 436-441.	1.9	86
23	Mephedrone (â€˜bath saltâ€™) elicits conditioned place preference and dopamine-sensitive motor activation. <i>Drug and Alcohol Dependence</i> , 2012, 126, 257-262.	3.2	100
24	Mephedrone (4-methylmethcathinone): What is new in our understanding of its use and toxicity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 39, 227-233.	4.8	62
25	â€˜Ivory waveâ€™ toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. <i>Clinical Toxicology</i> , 2012, 50, 108-113.	1.9	27
26	Monitoring a toxicological outbreak using Internet search query data. <i>Clinical Toxicology</i> , 2012, 50, 818-822.	1.9	68
27	Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion. <i>PLoS ONE</i> , 2012, 7, e45473.	2.5	56
28	Bath Salts: The Ivory Wave of Trouble. <i>Western Journal of Emergency Medicine</i> , 2012, 13, 58-62.	1.1	22
29	â€˜Our favourite drugâ€™: prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. <i>Journal of Substance Use</i> , 2012, 17, 91-97.	0.7	107
30	Analysis of First and Second Generation Legal Highs for Synthetic Cannabinoids and Synthetic Stimulants by Ultra-Performance Liquid Chromatography and Time of Flight Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2012, 36, 360-371.	2.8	110
31	A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 349-353.	1.9	20
32	Evidence of mephedrone chronic abuse through hair analysis using GC/MS. <i>Forensic Science International</i> , 2012, 218, 44-48.	2.2	53
33	Serotonin Syndrome Associated With MDPV Use: A Case Report. <i>Annals of Emergency Medicine</i> , 2012, 60, 100-102.	0.6	51
34	â€˜A Costly Turn Onâ€™: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. <i>International Journal of Drug Policy</i> , 2012, 23, 188-197.	3.3	82
35	Synthesis, full chemical characterisation and development of validated methods for the quantification of the components found in the evolved â€˜legal highâ€™-NRG-2. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 61, 122-135.	2.8	23
36	The Toxicology of Bath Salts: A Review of Synthetic Cathinones. <i>Journal of Medical Toxicology</i> , 2012, 8, 33-42.	1.5	591
37	<i>In vitro</i> metabolism studies on mephedrone and analysis of forensic cases. <i>Drug Testing and Analysis</i> , 2013, 5, 430-438.	2.6	98
38	Identification and differentiation of methcathinone analogs by gas chromatographyâ€“mass spectrometry. <i>Drug Testing and Analysis</i> , 2013, 5, 670-677.	2.6	17

#	ARTICLE	IF	CITATIONS
39	Analytical Techniques for the Detection of Novel Psychoactive Substances and Their Metabolites. , 2013, , 131-157.		5
40	Identification of novel psychoactive drug use in Sweden based on laboratory analysis “ initial experiences from the STRIDA project. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 400-406.	1.2	74
41	Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports. Drug and Alcohol Dependence, 2013, 132, 1-12.	3.2	126
42	Fatal Mephedrone Intoxication“ A Case Report. Journal of Analytical Toxicology, 2013, 37, 37-42.	2.8	75
44	Computer-aided (<i>in silico</i>) approaches in the mode of action analysis and safety assessment of Ostarine and 4-methylamphetamine. Human Psychopharmacology, 2013, 28, 365-378.	1.5	2
45	Elucidation of the Phase I and Phase II metabolic pathways of (±)-4-methylmethcathinone (4-MMC) and (±)-4-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS2. Journal of Pharmaceutical and Biomedical Analysis, 2013, 72, 177-185.	2.8	45
46	Differential effects of cathinone compounds and <scp>MDMA</scp> on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. British Journal of Pharmacology, 2013, 168, 966-977.	5.4	43
47	Mephedrone: Public health risk, mechanisms of action, and behavioral effects. European Journal of Pharmacology, 2013, 714, 32-40.	3.5	40
48	Investigating the “bath salt” panic: The rarity of synthetic cathinone use among students in the United States. Drug and Alcohol Review, 2013, 32, n/a-n/a.	2.1	38
49	Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacology, 2013, 229, 295-306.	3.1	107
50	“Bath Salts” and “Plant Food” Products: the Experience of One Regional US Poison Center. Journal of Medical Toxicology, 2013, 9, 42-48.	1.5	45
51	Methylenedioxypyrovalerone (“Bath Salts”), Related Death: Case Report and Review of the Literature,. Journal of Forensic Sciences, 2013, 58, 1654-1659.	1.6	150
52	Designer cathinones“ An emerging class of novel recreational drugs. Forensic Science International, 2013, 231, 42-53.	2.2	153
53	Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emergency Medicine Journal, 2013, 30, 70-71.	1.0	31
54	Substituted Cathinone Products. Journal of Addiction Medicine, 2013, 7, 153-162.	2.6	33
55	Mephedrone. , 2013, , 211-231.		2
56	Adolescent Synthetic Cathinone Exposures Reported to Texas Poison Centers. Pediatric Emergency Care, 2013, 29, 151-155.	0.9	14
57	Synthetic cathinone abuse. Clinical Pharmacology: Advances and Applications, 2013, 5, 109.	1.2	34

#	ARTICLE	IF	CITATIONS
59	Effects and Risks Associated with Novel Psychoactive Substances. Deutsches A&#x0308;rztblatt International, 2014, 111, 139-47.	0.9	75
60	Bath Salts, Mephedrone, and Methylenedioxypyrovalerone as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention. Advances in Pharmacology, 2014, 69, 581-620.	2.0	64
61	Liquid chromatography tandem mass spectrometry determination of selected synthetic cathinones and two piperazines in oral fluid. Cross reactivity study with an on-site immunoassay device. Journal of Chromatography A, 2014, 1374, 93-101.	3.7	57
62	Toxic Ingestions. , 2014, , 695-727.		0
63	Seizures Associated With Synthetic Cathinone Exposures in the Pediatric Population. Pediatric Neurology, 2014, 51, 67-70.	2.1	26
64	The preclinical pharmacology of mephedrone; not just <scp>MDMA</scp> by another name. British Journal of Pharmacology, 2014, 171, 2251-2268.	5.4	61
65	Emerging Drugs of Abuse. Emergency Medicine Clinics of North America, 2014, 32, 1-28.	1.2	96
66	Synthetic Cathinones (â€œBath Saltsâ€). Journal of Emergency Medicine, 2014, 46, 632-642.	0.7	131
67	Toxicological findings in a fatal multidrug intoxication involving mephedrone. Forensic Science International, 2014, 243, 68-73.	2.2	61
68	Sensitive hydrophilic interaction liquid chromatography/tandem mass spectrometry method for rapid detection, quantification and confirmation of cathinone-derived designer drugs for doping control in equine plasma. Rapid Communications in Mass Spectrometry, 2014, 28, 217-229.	1.5	13
69	Using poisons information service data to assess the acute harms associated with novel psychoactive substances. Drug Testing and Analysis, 2014, 6, 850-860.	2.6	31
70	Khat and synthetic cathinones: a review. Archives of Toxicology, 2014, 88, 15-45.	4.2	273
71	Current European data collection on emergency department presentations with acute recreational drug toxicity: Gaps and national variations. Clinical Toxicology, 2014, 52, 1005-1012.	1.9	40
72	Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Science International, 2014, 245, 126-132.	2.2	56
73	Emerging drugs of abuse. Disease-a-Month, 2014, 60, 110-132.	1.1	35
74	Psychostimulants and Movement Disorders. Frontiers in Neurology, 2015, 6, 75.	2.4	47
75	Cathinone Neurotoxicity (â€œThe â€œ3Msâ€). Current Neuropharmacology, 2015, 13, 21-25.	2.9	52
76	Behavioral sensitization following concurrent exposure to mephedrone and D-amphetamine in female mice. Behavioural Pharmacology, 2015, 26, 180-183.	1.7	15

#	ARTICLE	IF	CITATIONS
77	Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. International Journal of Drug Policy, 2015, 26, 78-83.	3.3	46
78	Characteristics of analytically confirmed 3-MMC-related intoxications from the Swedish STRIDA project. Clinical Toxicology, 2015, 53, 46-53.	1.9	74
79	Driving under the influence of synthetic phenethylamines: a case series. International Journal of Legal Medicine, 2015, 129, 997-1003.	2.2	42
80	Acute Methylenedioxypyrovalerone Toxicity. Journal of Medical Toxicology, 2015, 11, 185-194.	1.5	51
81	Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug and Alcohol Dependence, 2015, 150, 1-13.	3.2	80
82	Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Medical Weekly, 2015, 145, w14043.	1.6	136
83	Bath Salts in the Emergency Department. Journal of Addiction Medicine, 2015, 9, 94-98.	2.6	15
84	Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of "legal high"™ packages containing synthetic cathinones. Archives of Toxicology, 2015, 89, 757-771.	4.2	73
85	The Legal Highs of Novel Drugs of Abuse. Journal of Drug Abuse, 2016, 02, .	0.2	3
86	The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol. Systematic Reviews, 2016, 5, 195.	5.3	35
87	Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry, 2016, 16, 293.	2.6	68
88	Clinical Pharmacology of the Synthetic Cathinone Mephedrone. Current Topics in Behavioral Neurosciences, 2016, 32, 313-331.	1.7	28
89	Sensitization to the locomotor stimulant effects of "bath salt" constituents, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), in male Sprague-Dawley rats. Drug and Alcohol Dependence, 2016, 164, 128-134.	3.2	37
90	Mephedrone and 3,4-methylenedioxy-methamphetamine: Comparative psychobiological effects as reported by recreational polydrug users. Journal of Psychopharmacology, 2016, 30, 1313-1320.	4.0	22
92	The Toxicology of New Psychoactive Substances. Therapeutic Drug Monitoring, 2016, 38, 190-216.	2.0	39
93	3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions. Archives of Toxicology, 2016, 90, 1959-1973.	4.2	62
94	Metabolic profile of mephedrone: Identification of nor-mephedrone conjugates with dicarboxylic acids as a new type of xenobiotic phase II metabolites. Toxicology Letters, 2016, 240, 114-121.	0.8	21
95	11 analytically confirmed cases of mephedrone use among polydrug users. Clinical Toxicology, 2017, 55, 181-186.	1.9	15

#	ARTICLE	IF	CITATIONS
96	Structure-activity relationship for toxicity of $\pm$ -pyrrolidinophenones in human aortic endothelial cells. <i>Forensic Toxicology</i> , 2017, 35, 309-316.	2.4	13
97	Misuse of 2-(ethylamino)-1-(4-methylphenyl)-1-pentanone (4-MEAP), a synthetic cathinone. <i>Clinical Toxicology</i> , 2017, 55, 231-232.	1.9	10
98	“Bath Salts” the New York City Medical Examiner Experience: A 3-Year Retrospective Review. <i>Journal of Forensic Sciences</i> , 2017, 62, 695-699.	1.6	17
99	Novel Psychoactive Substances: Systematic Review and Evidence-Based Analysis of Literature. <i>Global Journal of Health Science</i> , 2017, 9, 1.	0.2	5
100	Acute neurotoxicology of drugs of abuse. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2017, 141, 485-505.	1.8	0
101	Toxicity of new synthetic amphetamine drug mephedrone On Rat Heart mitochondria: a warning for its abuse. <i>Xenobiotica</i> , 2018, 48, 1278-1284.	1.1	6
102	An observational study on the sub-acute effects of mephedrone on mood, cognition, sleep and physical problems in regular mephedrone users. <i>Psychopharmacology</i> , 2018, 235, 2609-2618.	3.1	34
103	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. <i>Frontiers in Pharmacology</i> , 2018, 9, 713.	3.5	14
104	Patterns of Acute Toxicity Associated with New Psychoactive Substances. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 475-494.	1.8	9
105	Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1561.	4.1	18
108	Appetitive Needs and Addiction. , 2020, , 3-11.		9
109	Behavioral Economics and Addictive Disorders. , 2020, , 12-22.		43
110	Sensitization of Incentive Salience and the Transition to Addiction. , 2020, , 23-37.		43
111	Philosophical Issues in the Addictions. , 2020, , 38-50.		0
113	Human Neurobiological Approaches to Hedonically Motivated Behaviors. , 2020, , 53-61.		43
114	Human Laboratory Paradigms in Addictions Research. , 2020, , 62-72.		0
115	Behavioral Economic Considerations of Novel Addictions and Nonaddictive Behavior: Research and Analytic Methods. , 2020, , 73-86.		46
116	Substance and Behavioral Addictions Assessment Instruments. , 2020, , 87-105.		2

#	ARTICLE	IF	CITATIONS
117	Qualitative Approaches to the Study of Substance and Behavioral Addictions. , 2020, , 106-118.		3
119	Neurobiology of Substance Addictions. , 2020, , 121-135.		43
120	Neurobiological Foundations of Behavioral Addictions. , 2020, , 136-151.		43
121	Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science. , 2020, , 152-170.		43
122	The Role of Culture in Addiction. , 2020, , 171-181.		2
123	The Physical and Social Environments as Determinants of Health: Implications for Substance and Behavioral Addictions. , 2020, , 182-198.		0
125	Adolescent Drug Misuse Prevention: Challenges in School-Based Programming. , 2020, , 201-214.		1
126	Treatment of Alcohol, Tobacco, and Other Drug (ATOD) Misuse. , 2020, , 215-229.		2
127	Prevention and Treatment of “Food Addiction”, 2020, , 230-240.		43
128	The Prevention and Treatment of Gambling Disorders: Some Art, Some Science. , 2020, , 241-253.		45
129	Prevention and Treatment of Sex Addiction. , 2020, , 254-261.		1
130	Passionate Love Addiction: An Evolutionary Survival Mechanism That Can Go Terribly Wrong. , 2020, , 262-270.		0
131	Prevention and Treatment of Compulsive Buying Disorder. , 2020, , 271-279.		43
132	Prevention and Treatment of Work Addiction. , 2020, , 280-287.		0
133	Gaming Disorder and Its Treatment. , 2020, , 288-294.		2
135	Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis. , 2020, , 297-306.		43
136	Novel Psychoactive Substances: A New Challenge for Prevention and Treatment. , 2020, , 307-325.		0
137	Impaired Physicians. , 2020, , 326-332.		0



#	ARTICLE	IF	CITATIONS
138	Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools. , 2020, , 333-339.		43
139	Food versus Eating Addictions. , 2020, , 340-351.		43
140	Measurement, Prevention, and Treatment of Exercise Addiction. , 2020, , 352-361.		0
141	Tanning as an Addiction: The State of the Research and Implications for Intervention. , 2020, , 362-372.		43
142	Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction. , 2020, , 373-385.		44
143	Anhedonia in Addictive Behaviors. , 2020, , 386-408.		0
144	Mindfulness-Based Interventions Applied to Addiction Treatments. , 2020, , 409-417.		43
145	American Legal Issues in Addiction Treatment and Research. , 2020, , 418-425.		0
147	What Are Club Drugs and NPS and Why Are They Important?. , 2020, , 3-4.		0
148	A Brief History of NPS Production and Distribution. , 2020, , 5-10.		0
149	Classification Framework for Club Drugs and NPS. , 2020, , 11-12.		0
150	The Clinical Challenge of Club Drugs and NPS. , 2020, , 13-22.		0
151	Stimulant Drugs: Introduction. , 2020, , 23-30.		0
152	Stimulant Drugs: Cocaine. , 2020, , 31-36.		0
153	Stimulant Drugs: Amphetamine-Type Stimulants. , 2020, , 37-37.		0
154	Stimulant Drugs: Synthetic Cathinones. , 2020, , 54-60.		0
155	Depressant Drugs: Introduction. , 2020, , 61-61.		0
156	Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL). , 2020, , 62-70.		0

#	ARTICLE	IF	CITATIONS
157	Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS. , 2020, , 71-77.		0
158	Depressant Drugs: Benzodiazepine NPS. , 2020, , 78-80.		0
159	Depressant Drugs: Ketamine and Its Analogues. , 2020, , 81-88.		0
160	Synthetic Cannabinoid Receptor Agonists (SCRAs). , 2020, , 89-98.		0
161	Hallucinogens. , 2020, , 99-106.		0
162	Stimulant Drugs: Methamphetamine. , 2020, , 38-45.		0
163	Stimulant Drugs: MDMA and Drugs with Similar Effects. , 2020, , 46-53.		0
167	Mephedrone and MDMA: A comparative review. Brain Research, 2020, 1735, 146740.	2.2	22
168	Designer drugs: mechanism of action and adverse effects. Archives of Toxicology, 2020, 94, 1085-1133.	4.2	138
169	The Psychiatric Characteristics of People on a Mephedrone (â€œbath saltsâ€œ) Binge. Substance Use and Misuse, 2020, 55, 1610-1617.	1.4	6
170	Synthetic cathinone poisoning from ingestion of drug-laced â€œinstant coffee packetsâ€œ in Taiwan. Human and Experimental Toxicology, 2021, 40, 1403-1412.	2.2	13
171	An updated review on synthetic cathinones. Archives of Toxicology, 2021, 95, 2895-2940.	4.2	59
172	Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Experimental Neurology, 2021, 343, 113778.	4.1	30
173	General management of the patient with novel psychoactive substance toxicity. , 2022, , 181-202.		0
174	Synthetic cathinones. , 2022, , 333-380.		1
175	Cathinones. , 2017, , 1485-1524.		1
177	Evidence of 2 Populations of Mephedrone Abusers by Hair Testing. Application to 4 Forensic Expertises. Current Neuropharmacology, 2017, 15, 658-662.	2.9	18
178	â€œLegal Highsâ€œâ€œ New Players in the Old Drama. Current Drug Abuse Reviews, 2011, 4, 122-130.	3.4	54

#	ARTICLE	IF	CITATIONS
180	The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research, 2017, 5, 1-138.	1.3	12
181	Nouvelles drogues. , 2012, , 507-547.		1
182	Cathinones. , 2016, , 1-40.		0
183	New psychoactive substances in Europe and Czech Republic. Psychiatrie Pro Praxi, 2018, 19, 96-100.	0.1	0
184	Clinical pattern of poisoning among patients declared as taking novel recreational drugs. International Journal of Occupational Medicine and Environmental Health, 2020, 33, 445-455.	1.3	0
187	SStopTox: An <i>in Silico</i> Alternative to Animal Testing for Acute Systemic and Topical Toxicity. Environmental Health Perspectives, 2022, 130, 27012.	6.0	38
188	Synthetic Cathinones. , 2022, , 240-266.		0
189	Role of Analytical Screening in the Management and Assessment of Acute Recreational Drug Toxicity. , 2016, , 208-218.		0
190	Mephedrone and New Psychoactive Substances. , 2016, , 94-126.		0
191	The <scp>Lâ€arginineâ€NOâ€cGMP</scp> pathway mediates the locomotor activity alterations during the expression of sensitization to mephedrone in mice. Clinical and Experimental Pharmacology and Physiology, 0, , .	1.9	0
192	Mephedrone â€“ a synthetic derivative of cathinone. Current Issues in Pharmacy and Medical Sciences, 2023, 36, 54-64.	0.4	0